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ABSTRACT OF DISSERTATION 
 
CALIBRATED SHORT TR RECOVERY MRI FOR RAPID MEASUREMENT OF 
BRAIN-BLOOD PARTITION COEFFICIENT AND CORRECTION OF 
QUANTITATIVE CEREBRAL BLOOD FLOW 
 
The high prevalence and mortality of cerebrovascular disease has led to the 
development of several methods to measure cerebral blood flow (CBF) in vivo. One of 
these, arterial spin labeling (ASL), is a quantitative magnetic resonance imaging (MRI) 
technique with the advantage that it is completely non-invasive. The quantification of CBF 
using ASL requires correction for a tissue specific parameter called the brain-blood 
partition coefficient (BBPC). Despite regional and inter-subject variability in BBPC, the 
current recommended implementation of ASL uses a constant assumed value of 0.9 mL/g 
for all regions of the brain, all subjects, and even all species. 
The purpose of this dissertation is 1) to apply ASL to a novel population to answer 
an important clinical question in the setting of Down syndrome, 2) to demonstrate proof of 
concept of a rapid technique to measure BBPC in mice to improve CBF quantification, and 
3) to translate the correction method by applying it to a population of healthy canines using 
equipment and parameters suitable for use with humans. 
Chapter 2 reports the results of an ASL study of adults with Down syndrome (DS). 
This population is unique for their extremely high prevalence of Alzheimer’s disease (AD) 
and very low prevalence of systemic cardiovascular risk factors like atherosclerosis and 
hypertension. This prompted the hypothesis that AD pathology would lead to the 
development of perfusion deficits in people with DS despite their healthy cardiovascular 
profile. The results demonstrate that perfusion is not compromised in DS participants until 
the middle of the 6th decade of life after which measured global CBF was reduced by 31% 
(p=0.029). There was also significantly higher prevalence of residual arterial signal in older 
participants with DS (60%) than younger DS participants (7%, p = 0.005) or non-DS 
controls (0%, p < 0.001). This delayed pattern of perfusion deficits in people with DS 
differs from observations in studies of sporadic AD suggesting that adults with DS benefit 
from an improved cardiovascular risk profile early in life. 
Chapter 3 introduces calibrated short TR recovery (CaSTRR) imaging as a rapid 
method to measure BBPC and its development in mice. This was prompted by the inability 
to account for potential changes in BBPC due to age, brain atrophy, or the accumulation of 
hydrophobic A-β plaques in the ASL study of people with DS in Chapter 2. The CaSTRR 
method reduces acquisition time of BBPC maps by 87% and measures a significantly 
higher BBPC in cortical gray matter (0.99±0.04 mL/g,) than white matter in the corpus 
callosum (0.93±0.05 mL/g, p=0.03). Furthermore, when CBF maps are corrected for 
 
 
   
 
BBPC, the contrast between gray and white matter regions of interest is improved by 14%. 
This demonstrates proof of concept for the CaSTRR technique. 
Chapter 4 describes the application of CaSTRR on healthy canines (age 5-8 years) 
using a 3T human MRI scanner. This represents a translation of the technique to a setting 
suitable for use with a human subject. Both CaSTRR and pCASL acquisitions were 
performed and further optimization brought the acquisition time of CaSTRR down to 4 
minutes which is comparable to pCASL. Results again show higher BBPC in gray matter 
(0.83 ± 0.05 mL/g) than white matter (0.78 ± 0.04 mL/g, p = 0.007) with both values 
unaffected by age over the range studied. Also, gray matter CBF is negatively correlated 
with age (p = 0.003) and BBPC correction improved the contrast to noise ratio by 3.6% 
(95% confidence interval = 0.6 – 6.5%). 
In summary, the quantification of ASL can be improved using BBPC maps derived 
from the novel, rapid CaSTRR technique. 
 
KEYWORDS: Cerebral Blood Flow, Arterial Spin Labeling, Brain-Blood Partition 
Coefficient, Magnetic Resonance Imaging, Calibrated Short TR Recovery 
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CHAPTER 1.  INTRODUCTION 
1.1 Cerebral Blood Flow 
For almost a century, scientists and physicians have been developing non-invasive 
imaging methods to measure blood flow in the brain [1]. The critical importance of 
perfusion to physiological function and the abundance of pathologies that can lead to its 
compromise emphasize the significance of those methods in diagnosing and treating 
neurological diseases. For example, cerebrovascular disease (CVD) is the second leading 
cause of death worldwide [2] and the fifth leading cause of death in the United States [3]. 
Alzheimer’s disease (AD) and other dementias represent the fifth leading cause of death 
globally and sixth in the US [2]. Each year these two causes account for more than 250,000 
deaths in the United States and more than 7.5 million deaths worldwide[2, 3]. 
The applications of perfusion imaging are extremely broad and represent valuable 
tools in both research and clinical care. In-vivo measurements of cerebral blood flow (CBF) 
are critical in the management of primary cerebrovascular diseases like acute ischemic 
stroke [4-6] or arteriovenous malformation [7, 8], with the results determining the 
administration of tissue plasminogen activator (tPA) [9] or surgical intervention [10]. 
Cerebral perfusion has also been identified as an important biomarker in studying and 
monitoring neurodegenerative diseases like Alzheimer’s disease [11], frontotemporal lobar 
degeneration [12], and vascular dementia [13]. In the case of AD it has been shown that 
individuals with genetic risk factors for dementia demonstrate reduced CBF decades in 
advance of cognitive impairment [14, 15]. Perfusion imaging is also common outside of 
the brain, particularly in the heart [16] and kidneys [17], and applications will continue to 
multiply with the advancement of imaging technologies. 
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1.2 Perfusion Imaging Techniques 
The earliest qualitative images of the cerebrovasculature were X-ray projections 
which employed iodinated contrast agents injected directly into the carotid artery [1]. Later, 
quantitative methods were developed to measure CBF based upon the principle of tracer 
dilution and Fick’s principle of mass balance in blood flow. The first qualitative 
experiments used inhaled tracers such as nitrous oxide (N2O) or radioactive xenon that 
were freely diffusible and whose concentration could be measured in the blood of the 
carotid artery and jugular vein [18, 19]. Quantitative CBF imaging was made possible with 
the development of X-ray computed tomography (CT) such that tracer concentration 
measurements could be resolved spatially [20]. Other radiolabeled tracers were developed 
for use in single-photon emission CT (SPECT) [21] and H215O positron emission 
tomography (PET) [22]. Improvements in the speed of CT scanners has enabled dynamic 
perfusion imaging using a bolus injection of iodinated contrast agent [23]. All of these 
techniques are in common use in clinical practice today, but they all share the important 
disadvantages of invasiveness and exposure to ionizing radiation. 
Perfusion imaging methods have also been developed for magnetic resonance 
imaging (MRI) with the significant advantage that this modality requires no ionizing 
radiation. The first MRI perfusion technique was dynamic susceptibility contrast (DSC) 
which used an intravenous injection of chelated gadolinium as an exogenous contrast agent 
[24]. Later, Williams et al. developed a completely non-invasive method to create perfusion 
weighted images by labeling the magnetic spins of the hydrogen protons of water 
molecules in the arterial blood (arterial spins) [25]. The labeled arterial spins would 
decrease the observed MRI signal relative to a control image where spins were not labelled, 
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with the difference in signal being proportional to CBF. This technique is called arterial 
spin labeling (ASL), and it has been the subject of growing interest due to its primary 
advantage of non-invasiveness.  
1.3 Arterial Spin Labeling 
1.3.1 Development 
The first implementation of ASL used a continuous stream of radiofrequency (RF) 
excitation and a slice-selective magnetic gradient to invert arterial spins in a narrow plane 
proximal to the imaging plane. Because the arterial spins are continuously labelled as they 
pass through the labeling plane this method is known as continuous ASL (CASL). Since 
the first description of CASL in 1992 numerous improvements have been made to address 
the various limitations of the early technique. Pulsed ASL (PASL) [26, 27], which uses a 
short RF pulse to label a thick slab of blood in the neck region, was developed to 
accommodate the more common RF transmitters that were unable to sustain the high duty 
cycles necessary for CASL as well as to improve tagging efficiency. Later, pseudo-
continuous ASL (pCASL) was developed which used a train of short pulses interspersed 
with a gradient wave to replicate the adiabatic inversion of CASL with lower RF deposition 
and less susceptibility to magnetization transfer effects [28]. Like PASL, pCASL does not 
require special equipment and has the benefit of greater signal to noise ratio (SNR), though 
not as high as CASL. Improvements were also made to the quantification model to account 
for arterial transit delays [29]. Due to the flexibility and variety of MRI sequences, there is 
an abundance of specific implementations within each of these broad categories.  
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1.3.2 Applications 
ASL has been applied to a wide range of normal and pathological conditions 
including normal aging [30, 31], ischemic injury [32, 33], epilepsy [34, 35], traumatic brain 
injury [36, 37], AD and other neurodegenerative diseases [12, 38, 39], neural neoplasm 
[40-42], and arteriovenous malformation [7]. Because there is no requirement for 
exogenous contrast or ionizing radiation, ASL has been used in pediatric populations [43] 
to study cerebral perfusion in sickle cell anemia [44] and congenital heart disease [45]. Pre-
clinical models of many of these diseases have been studied using ASL in dedicated small 
animal scanners [46-50]. There are also many examples of ASL perfusion measurements 
outside of the brain including the kidney [17], pancreas [51] and liver [52]. An important 
review by Alsop and colleagues describes the current recommended implementation for 
ASL in clinical applications[53]. 
1.3.3 Weaknesses 
The science of MRI, like many other fields, is composed of trade-offs. While ASL 
does have the advantage of being quantitative and completely non-invasive, it is a 
subtractive method and the amount of contrast derived from labeled arterial spins is 
relatively small. This leads to a low native SNR which must be improved with either large 
voxels or many averages. Large voxels yield low-resolution images and increasing the 
number of averages requires longer acquisition times.  
Another weakness of ASL arises when applying the quantification model to 
perfusion weighted images in order to create quantitative maps of CBF. The general kinetic 
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model is rigorously derived, however, its application typically requires some underlying 
assumptions to be made in practice. 
1.4 Arterial Spin Labeling Quantification 
1.4.1 Kety-Schmidt Equation and Tracer Kinetics 
To quantify CBF from an ASL acquisition it is necessary to apply a quantification 
model based on tracer kinetics. The models of tracer diffusion are well established going 
back to the N2O experiments of Kety and Schmidt in 1948 [18] and were unified into a 
general kinetic model for ASL by Buxton and colleagues in 1998 [29]. It was first 
demonstrated that the change over time in the concentration of a freely diffusible tracer in 
tissue is equal to the flow multiplied by the difference in concentration between the arterial 
input and venous output of the tissue. This is known as Fick’s principle of cardiac output 
[54] and can be expressed as, 
 𝑑𝑑𝑐𝑐𝑡𝑡(𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑓𝑓 ∙ �𝑐𝑐𝑎𝑎(𝑡𝑡) − 𝑐𝑐𝑣𝑣(𝑡𝑡)� (1.1) 
where 𝑐𝑐𝑡𝑡(𝑡𝑡), 𝑐𝑐𝑎𝑎(𝑡𝑡) and 𝑐𝑐𝑣𝑣(𝑡𝑡) are the concentrations of tracer in the tissue, arterial blood, 
and venous blood respectively and 𝑓𝑓 is the blood flow. If the tracer is well-mixed and 
freely-diffusible, 𝑐𝑐𝑡𝑡(𝑡𝑡) will be equal to 𝑐𝑐𝑣𝑣(𝑡𝑡) corrected for the relative solubility of the 
tracer in the tissue and the blood. This correction factor is called the brain-blood partition 
coefficient (BBPC) and is denoted as λ. Substitution and integration yields, 
  𝜆𝜆𝑐𝑐𝑣𝑣(𝑡𝑡) = 𝑐𝑐𝑡𝑡(𝑡𝑡) = 𝑓𝑓(𝑡𝑡) ∙ ∫ �𝑐𝑐𝑎𝑎(𝜏𝜏) − 𝑐𝑐𝑣𝑣(𝜏𝜏)�𝑑𝑑𝜏𝜏
𝑡𝑡
0  (1.2) 
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This equation was suitable for the Kety and Schmidt experiment that used 
continuous exposure to inhaled N2O to eventually reach a steady state, but it requires 
modification for use in ASL to account for a finite bolus of tracer, imperfect labeling of 
arterial spins, and time decay of the magnetic label due to the longitudinal relaxation rate 
of the blood, 𝑇𝑇1,𝑏𝑏. The following describes the derivation of the general kinetic equation 
for PASL, but it can be adapted to pCASL with only small modifications [29]. 
In ASL the tracer is hydrogen protons in the water molecules of the blood whose 
magnetic moments have been inverted. In a control image these arterial spins would add to 
the measured MRI signal, but in the labelled image the arterial spins have been inverted 
and therefore any arterial signal that remains after the time decay of the label is subtracted 
from the MRI signal. Thus, the tissue concentration is equal to half the difference between 
the control and labeled images: 
 𝑐𝑐𝑡𝑡(𝑡𝑡) = ∆𝑀𝑀 2⁄  (1.3) 
The arterial concentration of label is equal to the product of the maximal 
equilibrium magnetization of arterial spins, 𝑀𝑀0,𝑏𝑏; the labeling efficiency, 𝛼𝛼; and the arterial 
input function, 𝑐𝑐(𝑡𝑡): 
 𝑐𝑐𝑎𝑎(𝑡𝑡) = 𝛼𝛼 ∙ 𝑀𝑀0,𝑏𝑏 ∙ 𝑐𝑐(𝑡𝑡) (1.4) 
Instead of a venous concentration measurement, a residue function describes the 
combined washout of tracer from a voxel of interest and time decay of tracer label. This 
residue function, 𝑟𝑟(𝑡𝑡), is a function of flow, 𝑓𝑓, partition coefficient, 𝜆𝜆, and the T1 of the 
tissue: 
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 𝑟𝑟(𝑡𝑡) = 𝑒𝑒
−𝑓𝑓𝑡𝑡
𝜆𝜆 ∙ 𝑒𝑒
−𝑡𝑡
𝑇𝑇1,𝑡𝑡 (1.5) 
In this case the tissue concentration which is equivalent to ∆𝑀𝑀 2⁄  is expressed as 
the blood flow, ƒ, times the convolution of the arterial concentration with the residue 
function to yield the general kinetic equation: 
 ∆𝑀𝑀 = 2 ∙ 𝛼𝛼 ∙ 𝑀𝑀0,𝑏𝑏 ∙ 𝑓𝑓 ∙ ∫ 𝑐𝑐(𝑡𝑡) ∙ 𝑟𝑟(𝑡𝑡 − 𝜏𝜏)𝑑𝑑𝜏𝜏
𝑡𝑡
0  (1.6 
The arterial input function is a stepwise function which assumes a bolus with well-
defined leading and trailing edges and a labeling magnitude that decays with time 
according to T1,b: 
 𝑐𝑐(𝑡𝑡) =  �
0,                      𝑡𝑡 <  𝜏𝜏𝑎𝑎
𝑒𝑒
−𝑡𝑡
𝑇𝑇1,𝑏𝑏,       𝜏𝜏𝑎𝑎 < 𝑡𝑡 < 𝜏𝜏𝑑𝑑
0,                       𝑡𝑡 ≥ 𝜏𝜏𝑑𝑑
 (1.7) 
where 𝜏𝜏𝑎𝑎 and 𝜏𝜏𝑑𝑑 are the arrival times of the leading and trailing edges of the bolus 
at the voxel of interest. 
If the image acquisition is programmed to occur after an inflow time 𝑡𝑡 = 𝑇𝑇𝑇𝑇 > 𝜏𝜏𝑑𝑑, 
then Equations 1.4 and 1.5 can be substituted in to Equation 1.6 which is then solved for 𝑓𝑓 
yielding, 
 𝑓𝑓 = ∆𝑀𝑀
2∙𝛼𝛼∙𝑀𝑀0,𝑏𝑏
∙ 𝛿𝛿𝛿𝛿
(1−𝑒𝑒𝛿𝛿𝛿𝛿∙(𝑇𝑇𝑇𝑇−𝜏𝜏𝑎𝑎))
∙ 𝑒𝑒−𝛿𝛿1,𝑏𝑏∙𝜏𝜏𝑑𝑑 ∙ 𝑒𝑒−𝛿𝛿1,𝑎𝑎𝑎𝑎𝑎𝑎∙(𝑇𝑇𝑇𝑇−𝜏𝜏𝑑𝑑) (1.8) 
where 𝑅𝑅1 is the relaxation rate which is the inverse of 𝑇𝑇1, and 𝑅𝑅1,𝑏𝑏 is the relaxation rate of 
blood, 𝑅𝑅1,𝑎𝑎𝑎𝑎𝑎𝑎 =  𝑅𝑅1,𝑡𝑡 +
𝑓𝑓
𝜆𝜆
 is the apparent relaxation rate of the tissue, and 𝛿𝛿𝑅𝑅 = 𝑅𝑅1,𝑏𝑏 −
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𝑅𝑅1,𝑎𝑎𝑎𝑎𝑎𝑎. In practice the apparent relaxation rate of the tissue is very close to that of the blood 
such that 𝛿𝛿𝑅𝑅 approaches zero. This means Equation 1.8 can be reduced to, 
 𝑓𝑓 = ∆𝑀𝑀∙𝑒𝑒
𝑇𝑇𝑇𝑇
𝑇𝑇1,𝑏𝑏
2∙𝛼𝛼∙𝑀𝑀0,𝑏𝑏∙𝑇𝑇𝑇𝑇
[𝑚𝑚𝑚𝑚 𝑔𝑔 𝑠𝑠⁄⁄ ] (1.9) 
1.4.2 Assumptions 
The inflow time, 𝑇𝑇𝑇𝑇, is the delay between the initial labeling of arterial spins and 
image acquisition. This is a scan parameter selected by the operator to be long enough to 
ensure that the trailing edge of the bolus has had sufficient time to arrive in all voxels in 
the image volume but not so long that the label has undergone too much time decay. The 
labeling efficiency, 𝛼𝛼, has been shown to be 98% in PASL [55] and 85% in pCASL [28]. 
Ideally the 𝑇𝑇1,𝑏𝑏 and 𝑀𝑀0,𝑏𝑏 would be measured for each subject, however in practice these 
values are normally assumed. The error due to 𝑇𝑇1,𝑏𝑏 is generally small except in populations 
where hematocrit can change drastically such as in neonates. The common practice is to 
assume that 𝑇𝑇1,𝑏𝑏 = 1.65 𝑠𝑠 at 3T [56].  
1.5 Brain-Blood Partition Coefficient 
1.5.1 Role of BBPC 
The estimation of 𝑀𝑀0,𝑏𝑏 is not as straightforward. The standard of practice is to 
normalize the ∆𝑀𝑀 image using a separate proton density weighted acquisition. This is 
equivalent to dividing each voxel by the equilibrium magnetization of the tissue, 𝑀𝑀0,𝑡𝑡, 
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instead of the blood. The 𝑀𝑀0,𝑡𝑡 is then related to the 𝑀𝑀0,𝑏𝑏 through the brain-blood partition 
coefficient by recognizing that, 
 𝜆𝜆 = 𝑀𝑀0,𝑡𝑡
𝑀𝑀0,𝑏𝑏
 (1.10) 
For PASL, this yields the final quantification equation, 
 𝑓𝑓 = 6000∙𝜆𝜆∙∆𝑀𝑀∙𝑒𝑒
𝑇𝑇𝑇𝑇
𝑇𝑇1,𝑏𝑏
2∙𝛼𝛼∙𝑀𝑀0,𝑡𝑡∙𝑇𝑇𝑇𝑇
[𝑚𝑚𝑚𝑚 100𝑔𝑔 𝑚𝑚𝑚𝑚𝑚𝑚⁄⁄ ] (1.11) 
where the number 6000 is a unit conversion from mL/g/s to mL/100g/min [53]. 
Normalization to a proton density image has the advantage of correcting for 
inhomogeneities in excitation or in the receiver coil profile. However, the BBPC remains 
unknown and must be measured or assumed. 
1.5.2 Variability in BBPC 
The BBPC is a tissue specific parameter which varies greatly across the two main 
tissue types in the brain. In humans the average BBPC is reported as 0.98 mL/g in gray 
matter and 0.83 mL/g in white matter [57, 58]. Even among the various gray matter regions 
BBPC can vary as much as 20% [59]. The BBPC also varies with age, particularly in 
neonates where brain water content is higher than adults at the same time blood water 
content is lower than adults [57]. A study using C15O2 PET also demonstrated a 19% 
decrease in BBPC in regions of cerebral infarction [60]. BBPC can also vary with species 
with a study in macaques reporting an average gray matter BBPC of 0.78 mL/g [61]. 
Therefore, BBPC should be determined empirically for each voxel in the image for each 
subject. 
10 
 
1.5.3 Current Standards for BBPC in ASL 
Empirical BBPC measurement has been performed using MRI in both humans and 
mice using a similar technique [58, 62]. Using a series of fast low-angle shot (FLASH) 
gradient echo (GRE) acquisitions with varying repetition times (MR), it was possible to 
determine relative proton density in each voxel. These relative proton density maps were 
then calibrated to an absolute scale based on a series of phantoms placed alongside the 
subject’s head that were doped with an increasing concentration of deuterium oxide (D2O) 
which does not produce MRI signal. Unfortunately, these acquisitions were prohibitively 
long requiring approximately 30 minutes to acquire a single slice in humans and 130 
minutes to acquire ten slices in mice. This is unfeasible in the context of ASL techniques 
which require 4-6 minutes of acquisition time in humans and 15-20 minutes in mice. 
In their consensus report on the recommended implementation of ASL for clinical 
practice, Alsop and colleagues recommend using an assumed value of 0.9 mL/g instead of 
a specific BBPC correction [53]. This value represents the whole brain average water 
content as measured by Herscovitch and Raichle using desiccation of ex-vivo human brain 
samples [57]. Substituting a single average value for the entire brain into the ASL 
quantification model disregards the regional and inter-subject variability of BBPC, and 
represents a known weakness of the ASL technique. 
1.6 Dissertation Objectives 
The goal of the present work is 1) to describe the application of ASL in a novel 
population to answer an important clinical question in the setting of Down syndrome, 2) to 
demonstrate proof of concept of a rapid technique to measure BBPC in mice to improve 
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CBF quantification, and 3) to translate the correction method by applying it to a population 
of healthy canines using equipment and parameters suitable for use with humans. 
Chapter 2 is a report of an ASL study of adults with trisomy 21 or Down syndrome 
(DS). This population is particularly important in understanding the role of systemic 
cardiovascular risk factors on AD. Because amyloid precursor protein (APP) is encoded 
on chromosome 21, people with DS overexpress APP leading to the development of AD 
neuropathology as early as the fourth decade of life. The accelerated accumulation of beta 
amyloid (A- β ) is likely one of the causes of the  very high prevalence of dementia in 
people with DS after 50 years of age [63, 64]. In non-DS related AD, cerebrovascular 
neuropathology is thought to contribute in 6-45% of cases[65] with an observable decrease 
in CBF as much as two decades prior to the onset of dementia [11]. However, people with 
DS are protected from key cerebrovascular risk factors like atherosclerosis and 
hypertension. What was previously unknown was whether the accelerated A-β deposition 
in people with DS was accompanied by vascular dysfunction. The study in chapter 2 
measures global CBF using PASL in a cohort of participants with DS (age 26-65) and non-
DS controls (age 26-63). The results suggest that CBF drops significantly in people with 
DS during the 6th decade of life and other evidence of potential vascular dysfunction 
develops as well. It is possible that adults with DS benefit from an improved cardiovascular 
risk profile prior to age 50, but this is eventually overwhelmed by A-β deposition and the 
development of cerebral amyloid angiopathy (CAA). 
In the study described in chapter 2, the participants with DS were experiencing 
aging effects, brain atrophy, and the deposition of hydrophobic A-β plaques. All of these 
could potentially change the water balance of the brain and therefore the BBPC. It was not 
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feasible, however, to account for those changes with the currently available technique to 
measure BBPC non-invasively. Therefore a new method was developed to measure BBPC 
with an acquisition time comparable to that of ASL. 
Chapter 3 describes the novel, rapid BBPC measurement called calibrated short TR 
recovery (CaSTRR). The CaSTRR method is based on the previously described FLASH-
GRE technique, but reduces the acquisition time by 87%. The results of chapter 3 
demonstrate a significantly higher BBPC in cortical gray matter than in the white matter of 
the corpus callosum and improved contrast between gray and white matter regions of CBF 
maps when corrected for regional differences in BBPC. 
Chapter 4 describes the translation of the CaSTRR method for use with equipment 
and parameters suitable for use with human subjects. In this study CaSTRR and pCASL 
acquisitions were performed on a cohort of healthy canines using a 3T human scanner 
without special equipment. The results show that acquisition time was further reduced to 4 
minutes, BBPC did not vary across the age range studied but was significantly higher in 
gray matter than white matter, and BBPC correction again improved the contrast to noise 
ratio between gray and white matter regions of the CBF maps. It was also demonstrated 
that the CaSTRR technique can be further simplified by using hematocrit as a proxy value 
when calibrating the CaSTRR derived BBPC maps. All of this is evidence of the feasibility 
of using empirically derived BBPC measurements to improve CBF quantification when 
using ASL. 
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CHAPTER 2. GLOBAL CEREBRAL BLOOD FLOW IN PEOPLE WITH DOWN 
SYNDROME 
2.1 Introduction 
Down syndrome or trisomy 21 is the most common chromosomal disorder affecting 
13.5 of every 10,000 live births and leads to intellectual disability [66-68]. Improved 
medical care has brought about a significant extension in lifespan and quality of life for 
people with DS [69, 70]. However, older adults with DS are at high risk for developing 
dementia, with incidence and prevalence increasing substantially after 50 years of age [63, 
64]. Dementia in DS likely arises from Alzheimer’s disease (AD) neuropathology. AD 
neuropathology is typically observed after 30 years of age and involves both beta-amyloid 
(Aβ) deposition in plaques and neurofibrillary tangles [71].  The overexpression of APP 
on chromosome 21 is thought to be a key contributor to AD neuropathology and dementia 
in DS [72, 73]. 
Among typically developing individuals, AD commonly co-occurs with 
cerebrovascular disease (CVD). Estimates of a mixed etiology of AD with CVD range from 
5.7-45% in autopsy cases from the general population [65]. The contribution of 
cerebrovascular disease (CVD) to AD is increasingly being recognized as an important 
comorbidity that accelerates the age of onset of dementia and also leads to a faster 
progression of the disease [74, 75].  CVD can serve as a “second hit” necessary to develop 
clinical signs of dementia particularly when significant Aβ is present in the brain [76]. 
DS represents a unique opportunity to study the cerebrovascular features of aging 
and AD because people with DS exhibit fewer systemic vascular risk factors than those 
without DS. This population exhibits an absence of atheroma and lower blood pressure 
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than similarly aged adults without DS [77-79]. While other signs of CVD are rare in DS, 
cerebral amyloid angiopathy (CAA) has been described [80]. CAA is the deposition of Aβ 
in the walls of medium- and small-size leptomeningeal and cortical arteries, arterioles and, 
less frequently, capillaries and veins [80]. CAA can lead to micro- and macro-hemorrhages 
[81] and is observed in older individuals with DS [82-84]. Indeed CAA is more frequent 
in DS relative to older people with sporadic AD [85] and associated with 
microhemorrhages [86].  Thus, adults with DS represent an important cohort to study the 
relationship between CVD and AD because while people with DS accumulate CAA, the 
CAA occurs without atheroma and hypertension. 
Arterial spin labeling (ASL) is an advanced quantitative magnetic resonance 
imaging (MRI) technique that can measure cerebral blood flow (CBF) noninvasively and 
without the need for exogenous contrast agents [53, 87].  We hypothesized that 1) people 
with DS would show lower CBF by ASL than similarly aged people without DS and 2) 
CBF will decrease with age in DS. To test these hypotheses, pulsed ASL was used to 
acquire quantitative CBF maps from 35 cognitively characterized people with DS ranging 
in age from 26 to 65 years, with and without dementia. In addition, 15 people without DS 
ranging in age from 26-63 years served as a non-DS control group (CTL). 
2.2 Methods 
2.2.1 Participants 
ASL measures were collected from a single visit during an ongoing longitudinal 
study of aging in DS evaluating decline in cognitive functioning and neural integrity as 
predictors of the development of dementia [88].  We recruited participants older than 
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25 years through local DS support groups and residential facilities in Kentucky and 
southern Ohio from 2015-2016. We excluded participants if they had active and unstable 
medical conditions (e.g., cardiovascular complications). Because thyroid dysfunction is 
common in individuals with DS, we included these participants if their thyroid dysfunction 
was medically controlled. People with DS who were demented may have also been 
prescribed AD medications, and these individuals were also included in the study. Upon 
request, 13 participants were provided with Ativan to control claustrophobia while in the 
MRI scanner.  
Presence of dementia was determined using three sources of information reviewed 
by a consensus panel of three neurologists and two psychologists.  This panel reviewed 
medical history, physical and neurological exam findings, informant ratings, and mental 
status measures in order to reach a consensus diagnosis of DS with and without clinical 
dementia.  Informant measures included the Vineland Adaptive Behavior Scales (VABS) 
[89], Dementia Questionnaire (DMR) [90], and Neuropsychiatric Inventory (NPI) [91].  
Three primary cognitive measures were also included in the consensus review and 
incorporated the Severe Impairment Battery (SIB) [92], Brief Praxis Test (BPT) [93], and 
modified Fuld Object Memory Examination (FOME) [94].  Following standard clinical 
criteria for dementia [95, 96] a dementia classification required an informant report of 
functional decline. The study cohort included 35 adults with DS with 7 participants meeting 
criteria for dementia (DSAD+) (Table 1). 
We also recruited 15 age- and gender-matched (by frequency matching) non-DS 
control participants (CTL). CTLs reported no history of significant neurologic, 
cardiovascular, or psychiatric disorders and had no evidence of dementia. All participants 
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completed informed written consent or assent with guardian consent for the DS 
participants. The study and research procedures were approved by the University of 
Kentucky Institutional Review Board.  
2.2.2 ASL Methods and Analysis 
A three-dimensional (3D) pulsed ASL (PASL) sequence with a gradient and spin 
echo (GRASE) readout was used for cerebral blood flow (CBF) measurement [53]. The 
parameters were as follows: TR/TE/TI(inflow time)/TS(saturation time) 
=4500/13.04/1900/500 ms, slab thickness =154 mm, slice-selective labeling gradient = 
10mT/m, matrix = 64 x 64 x 44, FOV = 224 x 224 x 154 mm. Nine tagged and untagged 
data sets were acquired. Five additional M0 images were acquired with no labeling for CBF 
quantification. DS participants were more likely to move while in the scanner than the 
control participants, therefore we set a minimum number of non-motion corrupted datasets 
in order for the participant to be included in the analysis.  To be included in the analysis 
participants were required to have at least 6 tagged and untagged datasets and 3 M0 datasets 
not corrupted by motion artifact. In cases where more than 6 tagged and untagged datasets 
were valid, only the first 6 volumes were averaged to maintain a constant expected signal 
to noise ratio. A total of 10 participants did have at least one dataset excluded, however all 
participants met the minimum criteria to be included in the analysis.  
Selected data sets were co-registered using an intensity-based registration 
algorithm in Matlab (Mathworks, Natick, MA, USA) before being averaged to yield a 
tagged, an untagged and an M0 volume for each subject. Quantitative CBF maps (in 
ml/100g/min) were calculated using in-house Matlab software applying the equation [53], 
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 𝐶𝐶𝐶𝐶𝐶𝐶 =  6000 ∙ 𝜆𝜆 ∙�𝑆𝑆𝑇𝑇𝑢𝑢𝑢𝑢𝑡𝑡𝑎𝑎𝑢𝑢− 𝑆𝑆𝑇𝑇𝑡𝑡𝑎𝑎𝑢𝑢�∙ 𝑒𝑒
𝑇𝑇𝑇𝑇
𝑇𝑇1,𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑑𝑑
2 ∙ 𝛼𝛼 ∙ 𝑇𝑇𝑆𝑆 ∙ 𝑆𝑆𝑇𝑇𝑀𝑀0
 (2.1) 
where λ is the blood-brain partition coefficient (assumed to be 0.9 mL/g) [57], SIuntag and 
SItag are the average signal intensity of the untagged and tagged volumes respectively, 
T1,blood is the longitudinal relaxation time of the blood (assumed to be 1.65 seconds at 3.0T) 
[56], SIM0 is the average signal intensity of the M0 volumes, and α is the labeling efficiency 
(assumed to be 0.98 for PASL) [55]. 
For CBF analysis, a single ROI encompassing the entire brain volume was drawn 
manually with the assistance of the in-house Matlab software. This ROI was drawn using 
the M0 image for its higher contrast to noise ratio and included gray and white matter 
regions, ventricles, and cerebellum. Global CBF was calculated as the average of all voxels 
in the ROI 
2.2.3 Residual Arterial Signal Scoring 
Preliminary observation of the CBF maps revealed that in some subjects a portion 
of the ASL signal is retained in the large arteries of the brain. In severe cases, the residual 
arterial signal (RAS) gives the appearance of a low resolution angiogram. An example of 
minimal, moderate, and severe RAS is shown in Figure 2.1. To quantify the effect of this 
RAS, two expert reviewers who were blinded to participant information reviewed the same 
axial slice from each subject to determine if RAS was severe or not. A third blinded 
reviewer was consulted in the case of disagreement. The Cohen kappa statistic for inter-
observer agreement was κ = 0.79 (p < 0.001). 
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Figure 2.1 Representative CBF maps demonstrating residual arterial signal (RAS) 
2.2.4 Statistics 
People with DS were separated into an old and young cohort using a Jenks natural 
breaks optimization [97] such that intra-class variance is minimized. This yielded a 
discriminating age of 54 years. Participants were also subdivided by DS vs CTL, RAS 
score (severe or not), and gender. To determine the effect of age group and DS status on 
global cerebral blood flow, three-way ANOVA was performed while controlling for sex. 
Tukey’s test was used to correct for multiple comparisons, and values of p < 0.05 were 
considered significant. To determine differences in the prevalence of RAS and dementia 
among age groups and DS status, multi-layered contingency table analysis was performed 
with post-hoc analysis of standardized residuals.  
All statistics are reported as mean ± standard deviation. 
Statistical analysis was performed using Matlab and IBM SPSS Statistics (IBM 
Corp., Armonk, NY, USA) 
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2.3 Results 
2.3.1 Demographic Characteristics 
Table 2.1 displays the demographics and group means on the BPT,SIB, and DMR 
for the DS groups. Among the 35 adults with DS, 4 females were identified with dementia 
due to Alzheimer’s disease (DSAD). DSAD participants were significantly older (t(20.39) 
= -6.74; p < 0.001) had significantly higher scores on DMR (t(7.04) = -5.99; p < 0.001) 
compared to DS participants without dementia (referred to as DS).  There were no 
significant differences between DSAD and DS participants on the BPT (t(4.03) = 0.43; p= 
0.69) or SIB (t(3.96) = 1.48; p= 0.21). Levels of intellectual disability prior to a diagnosis 
of dementia did not differ between the participants with DS and DSAD (Fisher’s exact test 
p= 0.45) as the sample reflected a 50%/50% split of participants in the mild and moderate 
ranges overall and a 20%/30% split for those persons diagnosed with dementia.  
Table 2.1 Demographics 
Variable 
DS Control 
DS (n=35) DSAD+ (n=7) DSAD- (n=28) Ctl (n=15) 
Female 21 (60.00%) 4 (57.10%) 17 (60.70%) 11 (73.33%) 
Age 43.16 (11.12) 56.74 (4.64) 39.77 (9.55) 49.27 (11.64) 
BPT 70.50 (7.74) 69.00 (7.44) 70.71 (7.89) -- 
SIB 85.13 (11.83) 77.25 (11.35) 86.25 (11.66) -- 
DMR 16.38 (16.22) 42.29 (13.83) 9.67 (7.89) -- 
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2.3.2 Cerebral Blood Flow vs Age 
A plot of global CBF versus age reveals a clustering of people with DS over the 
age of 54 with significantly reduced CBF values (Fig. 2.2). This clustering is confirmed by 
Jenks natural breaks optimization which shows a maximal goodness of variance fit at 54 
years. All but one of the DS participants over this age had global CBF values lower than 
the minimum value of young DS participants. Age group was identified by ANOVA as the 
strongest contributor to reduced global CBF (p < 0.001), and while DS status was not 
significant as a main effect (p = 0.09) the interaction term between age group and DS status 
was significant (p = 0.034). This indicates that the CBF decrease with age is more 
pronounced among people with DS. Sex was not a significant factor. Post-hoc analysis 
determined that older people with DS had a significant 31% reduction in CBF (32.3 ± 9.6 
mL/100g/min) versus younger people with DS (46.7 ± 6.7 mL/100g/min, p < 0.001) (Fig 
2.3). While CTL subjects over the age of 54 years appeared to also have reduced CBF (40.9 
± 4.1 mL/100g/min) compared to younger controls (45.9 ± 5.8 mL/100g/min), this 
difference was not significant (p= 0.59). 
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Figure 2.2 Global CBF versus participant age. Participants with severe RAS are 
indicated with an X, and people with dementia with a square. The dotted line is the Jenks 
optimized age cutoff for people with DS (54 years), and beyond this age there is a drastic 
reduction in measured global CBF. The majority of DS participants with dementia as well 
as a majority of participants with severe RAS lie beyond this line. 
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Figure 2.3 Mean global CBF for old (>54) and young (<54) cohorts of DS and CTL 
participants. No significant difference was observed with age in the CTL participants 
(>54 = 40.9 ± 4.1 mL/100g/min vs <54 = 45.9 ± 5.8 mL/100g/min, p=0.59), but older DS 
participants demonstrate a 31% reduction in CBF (32.3 ± 9.6 mL/100g/min) versus 
younger people with DS (46.7 ± 6.7 mL/100g/min, p <0.001) (*** indicates p<0.001, 
error bars represent standard error of mean).   
2.3.3 Severe RAS and Dementia in People with DS 
Pearson chi squared analysis demonstrated dependence between severe RAS score, 
age group, and DS status (χ2 = 5.83, p = 0.016). Post-hoc analysis of standardized residuals 
demonstrates that people with DS over the age of 54 years had a significantly higher 
proportion of severe RAS scores (50%) vs younger people with DS (11%) or non-DS 
controls (0%) (p = 0.0078). Similar dependence was shown between dementia status, age 
group, and DS status (χ2 = 11.7, p < 0.001), and post-hoc analysis showed a much higher 
prevalence of dementia in older people with DS (63%) than younger people with DS (7%) 
or non-DS controls (0%, p < 0.001). 
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2.4 Discussion 
In this study we report a reduction in global CBF as measured by PASL in older 
people with DS. There are two underlying mechanisms that could account for this 
reduction, and both are likely contributors to our measurement. First, the reduced measured 
blood flow may be a true reduction in perfusion in older DS brain tissue compared to young 
DS and non-DS controls. Second, the lower measured CBF may be exaggerated by the 
sensitivity of the ASL technique to prolonged arterial transit times that manifest as RAS. 
Our measured CBF reduction in old versus young people with DS may represent a 
true reduction in perfusion. This is supported in the literature by a case study by Purdi, et 
al, in 1994 that described a marked decrease in cortical blood flow in a 52 year old person 
with DS (Purdi, et al., 1994). Another 2017 doppler study of 6 people with DS compared 
to 7 age matched controls showed a 30% reduction in carotid blood flow and a 20% 
reduction in vascular conductance (Wee, et. al., 2017). CAA can lead to micro and macro 
hemorrhages [98], and brain Aβ40 (typically associated with CAA) rises exponentially 
with age in DS [99]. CAA also affects older people with DS to a greater extent than in 
sporadic AD [85].Thus we conclude that one mechanism responsible for the observed 
reduction in global CBF is, in fact, due to reduced perfusion in older people with DS. 
A portion of the perfusion reduction may also be due to delayed arterial perfusion 
as indicated by severe RAS. Half of the older people with DS and 11% of younger people 
with DS in this comparison displayed severe RAS signs. The 3D GRASE readout of our 
PASL sequence is known to suppress the signal intensity of faster moving arterial blood 
with the rapid and repeated application of gradients similar to the signal suppression 
observed in diffusion weighted imaging [87]. Therefore, extreme delays in perfusion can 
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cause the blood bolus to remain in the large arteries and lead to an apparent suppression of 
the measured signal intensity. This causes an underestimate of the true CBF. Zaharchuk et 
al., 2009, observed a similarly low CBF in the watershed regions, last to perfuse, as 
measured by ASL in 18 out of 139 (13%) subjects using ASL when compared to normal 
bolus delivered perfusion MRI [100]. Our inflow time of 1900ms should be less sensitive 
to RAS than the 1500ms used by Zaharchuk et al., and the average age of the subjects that 
showed reduced CBF in that study was 71 yrs. Yet we have observed this phenomenon in 
4 out of 8 (50%) of our DS participants between the ages of 54-65 yrs. Though we are 
unable to quantify the ATT with only a single inflow time, it appears that ATT is delayed 
in DS compared with the CTL cohort based on the prevalence and severity of RAS.  There 
is a significant increase in severe RAS after the age of 54 years, and this delay is partially 
responsible for our decreased CBF measurements in old versus young people with DS. 
This is consistent with research demonstrating a 30% lower arterial conductance in DS in 
the carotid arteries (18-40yrs)  [101], a 15% increase in carotid stiffness in young DS vs 
nonDS [102], and a carotid-femoral pulse wave velocity that decreases faster with age in 
DS than nonDS (although this effect is not significant after a systolic blood pressure 
adjustment) [103]. Thus, even though this second possible mechanism is not a direct 
measure of reduced perfusion, it is still likely an indicator of changes in the 
cerebrovasculature. 
Higher blood flow velocities could be a result of stenosis due to atherosclerosis. 
However, given that our DS volunteers typically do not have atherosclerosis or 
hypertension, it is unlikely that this is an underlying factor for DS. It is more likely that 
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CAA may be contributing to the perfusion deficit by affecting blood vessels ability to dilate 
and constrict, whether mechanically or through autonomic dysregulation. 
The current study also provides some insight on the role of cerebrovascular 
dysfunction in DS. Previous imaging studies show the effects of vascular deficits on white 
matter (WM) in DS. An interesting observation from our first WM integrity studies using 
diffusion tensor imaging (DTI) was that there is a periventricular distribution of WM 
integrity losses, and this is a region that typically shows white matter hyperintensities 
(WMH) in sporadic AD [104]. WMH volume, particularly in parietal regions, is elevated 
among individuals with and at risk for AD, predicts future diagnosis of AD, and predicts 
the rate of progression of cognitive symptoms among individuals with AD [105]. Further, 
previous studies show that ex vivo imaging of autopsy brain indicates an overlap between 
fractional anisotropy (FA) in DTI studies and WMH that reflect vascular deficits [106], 
and WMH prominent in periventricular regions lead to reduced FA [107]. However, these 
studies do not capture the progression of vascular dysfunction with age, particularly as it 
relates the onset of dementia.  
Virtually all DS adults have sufficient neuropathology for a diagnosis of AD by 40 
years [108-110], including senile plaques (SP-beta-amyloid (Aβ) protein) and 
neurofibrillary tangles (hyperphosphorylated tau protein). This is largely due to the third 
copy of chromosome 21 in DS because Aβ is derived from the β-amyloid precursor protein 
(APP) on chromosome 21 [111]. Aβ accumulation in diffuse plaques does not begin 
systematically until after the age of 30 years [108]. Between the ages of 30 and 40 years, 
neuropathology accumulates until it reaches levels sufficient for AD [110].  
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What was previously unknown was whether this accumulation of Aβ was 
accompanied by vascular dysfunction in DS. This is particularly relevant because of the 
increasing evidence of the role of CVD in the development and progression of sporadic 
AD. In late onset AD, reduced CBF precedes the transition to dementia by decades [112], 
and mixed etiology dementia is very common [65]. In this study, by contrast, we do not 
observe a reduction in measured CBF among people with DS until the middle of the 6th 
decade, corresponding to the typical age of onset for dementia in this population. This 
suggests that the protective vascular profile (absence of atheroma and reduced blood 
pressure) of DS may work to delay the progression of AD until it is overwhelmed by 
amyloidopathy. Supporting this hypothesis are data showing the impact of amyloid on 
endothelial cell function [113]. 
In a previous study of 70 adults with DS ranging in age from 40-66 years, there was 
an absence of atheroma and lower blood pressure than similarly aged adults without DS 
[77]. Other studies also report low frequencies of atherosclerosis and arteriolosclerosis [78, 
79, 85].  
While these common signs of CVD are rare in DS, CAA is consistently observed 
in older individuals with DS >55 yrs [82-84]. CAA is the common term used to define the 
deposition of amyloid in the walls of medium- and small-size leptomeningeal and cortical 
arteries, arterioles and, less frequently, capillaries and veins. These depositions contain 
post-translationally modified Aβ [114] and can lead to micro and macro hemorrhages [98]. 
Importantly, people with DS show more extensive and severe CAA than older people with 
sporadic AD [85]. Furthermore, the same study shows that the transition to severe CAA in 
DS occurs in the sixth decade [85] around the same age as the drop in global CBF observed 
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in this study. Interestingly, there are reports that CAA in DS is associated with extensive 
hemorrhages in some studies (Belza and Urich, 1986; Donahue et al., 1998; McCarron et 
al., 1998; Mendel et al., 2010; Naito et al., 2008) but not in others [82, 83]. Buss and 
colleagues discuss in their review whether people with DS are protected from strokes [115]. 
Micro and macro hemorrhages that result from CAA typically manifest as WMH, and 
preliminary data from our study shows that by SWI, we can identify hypointensities 
consistent with CAA , and we have published data showing that brain Aβ40 (typically 
associated with CAA) rises exponentially with age in DS [99]. 
Future longitudinal studies involving this cohort will be important to establish the 
sequence of CAA and perfusion deficits. Also, our study included only one inflow time 
and was therefore unable to calculate ATT, future studies with multiple inflow times would 
be able to generate maps of ATT to better investigate the change in vascular delivery 
occurring with age in DS. While we observed some interesting regional patterns, namely a 
more pronounced deficit in parieto-occipital regions of patients with severe RAS, we were 
not able to acquire specific regional volumes of interest for analysis. Regional analysis is 
particularly difficult in this population due to a lack of a standard atlas for the DS brain. 
Furthermore, motion artifacts are common in high resolution anatomical images when 
scanning people with DS. This makes coregistration and automatic segmentation extremely 
challenging, and manual regional segmentation was not feasible at this time. 
There have been few studies investigating the role of CVD on aging, cognition and 
dementia in DS. Based upon autopsy studies, there should be significant CVD that could 
be captured and quantified by the appropriate MR imaging protocols. In terms of designing 
future clinical trials, characterizing the age of onset and extent of CVD in adults with DS 
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will be critical given that CVD is mediated to large extent by lifestyle factors that are 
amenable to intervention.  
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CHAPTER 3. NOVEL CALIBRATED SHORT TR RECOVERY (CASTRR) 
METHOD FOR BRAIN-BLOOD PARTITION COEFFICIENT 
CORRECTION IN MICE 
3.1 Introduction 
Arterial spin labeling (ASL) is a non-invasive, quantitative magnetic resonance 
imaging (MRI) technique used to measure cerebral blood flow (CBF) in a wide variety of 
human conditions. A growing number of studies are using ASL to measure perfusion in a 
variety of preclinical murine models including, aging [116, 117], Alzheimer’s disease [47, 
118, 119], ischemic injury [50, 120, 121], traumatic brain injury [48], and vascular 
dementia [49]. This technique is based on using magnetically labeled protons on water 
molecules in the blood as a tracer substance to measure perfusion. As in other tracer-based 
techniques, in order to accurately quantify perfusion it is necessary to determine the 
partition coefficient of the tracer, which is in this case the relative solubility of water in the 
brain tissue vs the blood. The brain-blood partition coefficient (BBPC) is tissue-specific 
and varies with age, species, pathology, and particularly with brain region [57, 60-62]. 
Thus the BBPC must be measured directly, and while MRI is well suited to measure water 
content in the brain, the current techniques to do so have prohibitively long acquisition 
times [58, 62]. Because of this, it is standard practice in ASL quantification to assume a 
BBPC value of 0.9 mL/g based on desiccation experiments performed on ex-vivo human 
brain tissue [53, 57]. This global average value is used for all regions of the brain, all ages 
and pathologies, and is even adopted when performing ASL in mice [122-125]. 
Previous studies have determined a wide range of BBPC values in the human brain, 
particularly between relatively lipophilic white matter (0.82mL/g) and hydrophilic gray 
matter (0.99mL/g) [57, 59, 126]. Yet even among gray matter regions the BBPC can vary 
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as much as 20% [59]. Measurements in non-human primates have demonstrated lower 
BBPC values than humans with an even greater regional variability [61]. An MRI study of 
BBPC in mice reported an average BBPC of 0.89mL/g with little regional variability 
among gray matter regions of interest, but no white matter BBPC values were reported 
[62]. Because ASL has inherently low signal-to-noise ratio and the resolution requirements 
of scanning mouse brains are particularly high, it is necessary that the quantification 
methods introduce as little error as possible. Failure to correct for intra-subject regional 
variability as well as inter-subject variability in BBPC may result in a loss of sensitivity to 
perfusion deficits when using ASL. This is especially true when studying white matter 
regions which have both lower perfusion and lower BBPC. 
In this study, we used a calibrated short TR recovery (CaSTRR) MRI sequence to 
measure proton density. This protocol is similar to one used previously by Leithner et al. 
to measure BBPC in mice [62], but has been modified to greatly reduce the acquisition 
time. Proton density was determined for the brain tissue as well as a fresh sample of each 
mouse’s blood placed adjacent to the animal’s head in order to calculate BBPC. Then 
cerebral perfusion was measured using a pseudo-continuous ASL (pCASL) technique to 
compare CBF maps that were uncorrected to maps that were corrected for regional BBPC. 
Particular attention was given to the white matter region of interest in the corpus callosum. 
3.2 Methods 
3.2.1 Animal Model 
All animal experiments were performed in accordance with NIH guidelines and 
approved by the University of Kentucky Institutional Animal Care and Use Committee 
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(Approval number #2014-1264). Male C57Bl/6N mice aged 12 months (n=8) were 
acquired from the National Institute of Aging colony. MRI experiments were performed 
using a 7T MR scanner (Clinscan, Brüker BioSpin, Germany) at the MRI and Spectroscopy 
Center at the University of Kentucky. Mice were anesthetized using a 4% mixture of 
isoflurane with air for induction and then maintained using 1.2% isoflurane such that the 
respiration rate was kept within 50-80 breaths/min. Rectal temperature was also monitored 
continually and maintained at 37 ± 1°C using a water-heated bed. 
While under anesthesia a fresh blood sample was taken from the facial vein and 
sealed in a glass capillary tube with ethylenediaminetetraactetate (EDTA) as an 
anticoagulant. This sample was then placed adjacent to the head of the mouse in order to 
measure the proton density of the blood (Fig. 3.1-A). 
 
 
 
 
32 
 
 
Figure 3.1 Explanation of the calibrated short repetition time recovery (CaSTRR) 
imaging protocol to measure BBPC. (A) One CaSTRR acquisition showing the 
placement of blood and gadolinium doped phantoms in relation to the head of the mouse. 
(B) A representative series of FLASH-GRE images used for the CaSTRR method. (C) A 
representative signal recovery curve from a single voxel of brain tissue located in the 
cortex region of interest (circles) along with the exponential regression used to estimate 
the relative proton density of the voxel (line). (D) A representative map of relative proton 
density derived from the voxel-wise signal recovery curves. (E) The final BBPC map 
calculated as the ratio of proton density in the brain to the average proton density of the 
blood phantom and corrected for the density of brain tissue. 
3.2.2 Calibrated Short TR Recovery Imaging Protocol 
Both CaSTRR and pCASL images were acquired consecutively in a single imaging 
session. Because the CaSTRR acquisitions and the pCASL acquisitions require different 
receiver coils, a custom 3-D printed nose was developed to accommodate both a birdcage 
style volume coil and a phased-array surface coil so that the coils could be changed without 
disturbing the orientation of the mouse. This nose cone also facilitated the placement of 
phantoms adjacent to the head of the mouse. 
Mice were scanned with a series of five phantoms placed alongside their head in 
the scanner (Fig. 3.1-A). The phantoms contained a mixture of deuterium oxide with 
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distilled water such that the water contents of the phantoms were 60, 70, 80, 90 and 100% 
distilled water [62]. The phantoms were also doped with 0.07mM gadobutrol (Gadavist, 
Bayer Healthcare Pharmaceuticals, Whippany NJ, USA) such that the longitudinal 
relaxation rate (T1) was similar to the T1 of brain tissue (~1.6s at 7T) [127].  
The CaSTRR proton density measurements were acquired using a 39mm birdcage 
transmit/receive coil to ensure the most uniform coil sensitivity profile possible. To 
measure the proton density a series of image stacks was acquired using a phase-spoiled, 
fast low-angle shot gradient echo (FLASH-GRE) sequence with varying repetition times 
(TR = 125, 187, 250, 500, 1000, 2000 ms) (Fig. 3.1-B). The shortest possible echo time 
(TE = 3.2 ms) was used to minimize T2* decay. In order to improve signal to noise, 
multiple averages were taken for the images with TR = 125 ms (4 averages), 187 ms (4 
averages) and 250 ms (2 averages). Image matrix parameters were as follows: field of view 
= 2.8 cm x 2.8 cm, matrix = 256 x 256, in-plane resolution = 0.11 mm x 0.11 mm, slice 
thickness = 1mm, number of slices = 10, flip angle = 90°, acquisition time = 17 minutes 
[62].  
BBPC maps were calculated in a voxel-wise manner by first fitting the signal 
recovery curve (Fig. 3.1-C) to the mono-exponential equation S= M0*[1-e^(TR/T1)] to 
yield a map of M0 (Fig 3.1-D). Next the M0 map was normalized to the respective phantom 
series by fitting a linear regression to the average M0 value in each phantom. Finally, the 
proton density in each voxel of the brain was compared to the average proton density of 
the blood ROI using the equation BBPC= M0,brain/(M0,blood *1.04g/mL) (Fig. 3.1-E) [58, 
62].  
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3.2.3 Pseudo-Continuous ASL Protocol 
For pCASL acquisitions, paired control and label images were acquired using a 
four-channel phased-array surface receive coil for increased signal to noise, and a whole 
body volume transmit coil  to improve the tagging efficiency of the blood [119]. Image 
pairs were acquired in an interleaved fashion with a train of Hanning window-shaped 
radiofrequency pulses of duration/spacing = 200/200 μs, flip angle = 25° and slice-selective 
gradient = 9 mT/m, and a labeling duration = 2100 ms. The images were acquired by 2D 
multi-slice spin-echo single shot echo planar imaging with FOV =1.8 cm x 1.3 cm, matrix 
= 128 × 96, in-plane resolution = 0.14 mm x 0.14 mm, slice thickness = 1 mm, 6 slices, 
TE/TR = 20/4000ms, label duration = 1600ms, post-label delay = 0s, and averages = 120. 
A separate, unlabeled acquisition with TR = 10s and averages = 6 was used to normalize 
for the receiver coil profile. Total acquisition time for pCASL was 9 minutes. 
When analyzing the CBF maps, the two centermost slices containing the 
hippocampus were selected for analysis. The brain regions of the CaSTRR and pCASL 
images were isolated independently using an automated skull-stripping algorithm and then 
coregistered using an intensity based registration algorithm. The quantitative CBF maps 
were calculated from the pCASL images according to the equation [53] 
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, (3.1) 
where PLD is post-label delay, LD is label duration, T1,blood is the longitudinal relaxation 
of blood (2.2s at 7T), and α is label efficiency (0.85) [53]. For standard CBF maps the 
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BBPC was assumed to be a constant 0.9mL/g. Then a corrected CBF map was calculated 
by using the CaSTRR derived BBPC maps in place of the assumed constant.  
3.2.4 Image Analysis 
Regions of interest encompassing the superior neocortex, corpus callosum, and 
hippocampus were drawn manually on each analyzed slice. BBPC, uncorrected CBF, and 
corrected CBF values were averaged for each region of interest. Gray-white contrast was 
determined for each slice as the absolute difference of average CBF values in gray and 
white matter regions of interest. All analysis was performed with in-house written scripts 
in Matlab (Mathworks, Natick, MA, USA). 
3.2.5 Statistics 
Statistical analysis was performed using SPSS (IBM, Armonk, New York, USA).  
All data are expressed as mean ± standard deviation. Group comparisons were assessed 
using one- and two-way analysis of variance with Tukey’s post-hoc test. Values of p < 0.05 
were considered statistically significant. 
3.3 Results 
3.3.1 Corpus Callosum Demonstrates Reduced BBPC Compared To Neocortex 
The average BBPC values in the neocortex, corpus callosum, and the hippocampus 
were determined for each mouse and the average of all mice is reported in Table 1. The 
highest BBPC value was observed in the neocortex (µCtx = 0.99 ± 0.04 mL/g) which was 
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significantly higher than the corpus callosum (µCC = 0.93 ± 0.05 mL/g, p = 0.035), and 
also higher than the hippocampus, though not significantly (µHC = 0.95 ± 0.4 mL/g, p = 
0.17) (Figs. 3.2 & 3.3).  
Table 3.1 Mean Partition Coefficient and Perfusion Values by Region 
Regional Values Neocortex Hippocampus Corpus Callosum 
BBPC (mL/g) 0.99 ± .04 0.95 ± 0.04 0.93 ± 0.05 
CBF, uncorrected (mL/g/min) 2.81 ± 0.4 2.90 ± 0.6 1.44 ± 0.3 
CBF, corrected (mL/g/min) 3.09 ± 0.5 3.07 ± 0.7 1.51 ± 0.4 
Gray-White Perfusion Contrast 
Neocortex vs 
Corpus 
Hippocampus vs 
Corpus 
ΔCBFUncorrected (mL/g/min) 1.39 ± 0.4 1.46 ± 0.4 
ΔCBFCorrected (mL/g/min) 1.59 ± 0.5 1.54 ± 0.4 
Contrast improvement (%, 95% CI) 14.2%, 9.6-18.8% 5.8%, 1.4-10.1% 
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Figure 3.2 Representative maps of BBPC and CBF. Maps of BBPC (A) demonstrates 
elevated BBPC in the neocortex relative to the corpus callosum and hippocampus (µCtx= 
0.99 ± 0.04mL/g, µCC= 0.93 ± 0.05mL/g, µHc= 0.95 ± 0.04mL/g). Maps of the 
uncorrected (B) and BBPC-corrected (C) cerebral blood flow demonstrate the improved 
contrast between gray matter in the neocortex (top) and hippocampus (bottom) and the 
white matter in the corpus callosum (middle). While only one side is shown, regions of 
interest were drawn bilaterally and applied equally to all three maps. 
 
 
 
Figure 3.3 Regional analysis of BBPC  demonstrates significantly higher BBPC in the 
neocortex relative to the corpus callosum (µCtx= 0.99 ± 0.04mL/g, µCC= 0.93 ± 0.05mL/g, 
p = 0.035), while the hippocampus had a BBPC of µHc= 0.95 ± 0.04mL/g. 
3.3.2 Corpus Callosum Demonstrates Lower Perfusion than Gray Matter 
Elevated perfusion in gray matter regions was observed relative to the corpus 
callosum in both uncorrected CBF maps and maps with voxel-wise BBPC correction (Fig. 
3.4). In the uncorrected maps the hippocampus demonstrated the greatest perfusion (2.90 
± 0.6 mL/g/min) followed by the neocortex (2.81 ± 0.4 mL/g/min) with significantly less 
perfusion in the corpus callosum (1.44 ± 0.3 mL/g/min, p<0.001). However, when the maps 
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were corrected for BBPC the perfusion in the neocortex was highest (3.09 ± 0.5 mL/g/min) 
followed by the hippocampus (3.07 ± 0.7 mL/g/min) with significantly less perfusion again 
in the corpus callosum (1.51 ± 0.4 mL/g/min, p<0.001). None of the regions demonstrated 
significant changes in average CBF values due to BBPC correction (corrected vs 
uncorrected CBF, pCtx = 0.31, pCC = 0.66, pHC = 0.61). 
 
Figure 3.4 CBF by Region  The gray matter regions of the neocortex (µuncorrected= 2.81 ± 
0.4mL/g/min, µcorrected= 3.09 ± 0.5mL/g/min) and hippocampus (µuncorrected= 
2.90±0.6mL/g/min, µcorrected= 3.07 ± 0.7mL/g/min) demonstrate significantly higher 
cerebral blood flow than the white matter corpus callosum (µuncorrected= 1.44 ± 
0.3mL/g/min, µcorrected= 1.51 ± 0.4mL/g/min) in both the uncorrected and BBPC-
corrected CBF maps. (*** indicates p<0.001). 
3.3.3 Corrected CBF Maps Demonstrate Greater Contrast than Uncorrected 
When perfusion in gray matter regions is compared to the white matter of the corpus 
callosum for each mouse, the average difference in perfusion for the neocortex is 1.39 ± 
0.4 mL/g/min in the uncorrected maps, but it is 1.59 ± 0.5mL/g/min in the BBPC corrected 
maps, this constitutes a 14.2% increase in contrast between these regions (95% CI = 9.6-
18.8%). For the hippocampus the difference in perfusion is 1.46 ± 0.4 mL/g/min in the 
39 
 
uncorrected maps and 1.54 ± 0.4 mL/g/min in the corrected maps, or a 5.8% improvement 
(95% CI = 1.4%-10.1%) (Fig. 3.5 and Table 1). 
 
Figure 3.5 Improved contrast from BBPC correction. Contrast between the neocortex 
and corpus callosum was improved by 14.2% (95% CI= 9.6-18.8%, ΔCBFuncorrected = 1.39 
± 0.4mL/g/min, ΔCBFcorrected = 1.59 ± 0.5 mL/g/min) and between the hippocampus and 
corpus callosum by 5.8% (95% CI= 1.4-10.1%, ΔCBFuncorrected = 1.46 ± 0.4mL/g/min, 
ΔCBFcorrected = 1.54 ± 0.4mL/g/min). (* indicates p<0.05, ** indicates p<0.01). 
3.4 Discussion 
Using CaSTRR imaging we were able to produce high quality BBPC maps suitable 
for voxel-wise correction of perfusion measurements much faster than previous 
demonstrated. We determined that the average BBPC in the neocortex was 0.99 ± 0.04 
mL/g and in the hippocampus the BBPC was 0.95 ± 0.4 mL/g. We also determined the 
BBPC in the white matter structure of the corpus callosum to be 0.93 ± 0.05 mL/g which 
has not previously been reported in mice. We also found significantly lower CBF in the 
corpus callosum than the neocortex and the hippocampus. Finally, when CBF maps were 
corrected for regional variability in BBPC the gray-white matter contrast was improved by 
as much as 14%. 
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The significant reduction in the acquisition time of BBPC maps to only 17 minutes 
increases the feasibility of including such a scan during an ASL protocol. We were also 
able to perform a voxel-wise correction due in part to the custom nose cone designed to 
immobilize the mouse’s head while receiver coils are changed. The result of this correction 
is improved sensitivity to regional perfusion differences in CBF. This study acquired high 
resolution BBPC maps as was done in previous studies, but those maps had to be down-
sampled by 22% to match the resolution of the pCASL acquisition when calculating CBF. 
This means that further gains could be made in either acquisition time or signal to noise 
ratio by acquiring CaSTRR images at the same resolution as the ASL image. Furthermore, 
since the original BBPC mapping technique was adapted to use in mice from a previously 
established technique in humans, CaSTRR imaging should be rapidly translatable back to 
the clinical setting [58]. In fact, a recently published study on healthy human volunteers 
demonstrated that an alternative method of correcting CBF maps for BBPC variability also 
resulted in increased contrast between gray and white matter [128]. This is consistent with 
our study and highlights the potential benefit of BBPC correction. 
The improved regional specificity of CBF maps that are corrected for BBPC 
variability will be particularly relevant in the study of white matter pathologies [129]. 
There is growing interest in vascular dysfunctions that accompany commonly observed 
white matter pathologies like multiple sclerosis [130, 131], white matter hyperintensities 
[132], and schizophrenia [133]. The inherently low signal to noise of ASL is exacerbated 
in white matter where there is far less perfusion than gray matter. This means differences 
in perfusion will be even more subtle and could be confounded by changes in BBPC. While 
adding a second measurement to the CBF calculation with its inherent noise may introduce 
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more variability in the CBF maps, the ability to account for significant differences in BBPC 
may increase sensitivity when comparing groups or regions with small perfusion 
differences. 
It should be noted that the CaSTRR technique differs from the one described by 
Leithner et al. in a few key aspects. The primary difference is the choice to use 
logarithmically spaced TRs and omit TRs longer than 2 seconds. This change reduced the 
acquisition time by 87% from ~130 minutes [62] to 17 minutes. In previously published 
BBPC results, phantoms consisted of pure H2O/D2O solutions with very long T1 recovery 
times which necessitated long TRs [58, 62]. By adding gadolinium to the water phantoms 
we were able to reduce the T1 of the phantoms to approximately match the tissue thereby 
obviating the long TR scans that accounted for the vast majority of scan time. It should 
also be noted that Leithner et al. used 8-16 week old 129S6/SvEv mice. We would expect 
younger mice to have a higher BBPC than the 12 month old mice used in our experiment, 
however we observed higher BBPC values in our C57Bl/6N mice than were reported by 
Leithner et al. Future studies will need to consider the possibility that BBPC could vary 
with genetic strain. 
There are several limitations to this study. While previous studies have used a 
uniform phantom to try and correct for the field inhomogeneity, variations were typically 
less than 5% and it is unlikely that the B1 field will be the same in a uniform phantom as 
it is while scanning a mouse [58, 62]. For this reason we chose not to perform any post-
hoc field correction and instead assumed a uniform field and receiver profile. More 
advanced field correction techniques may be useful. Also this study did not include a 
comparison to a post-mortem desiccation experiment. The standard BBPC mapping 
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technique has been shown to underestimate the BBPC when compared to desiccation 
because a small fraction of water in the brain tissue does not contribute to the MRI signal 
[62]. Thus the overestimation of BBPC by CaSTRR may compensate for this effect, though 
not because it is more sensitive to this hidden water. Furthermore, regional analysis is not 
possible with desiccation, so desiccation could not confirm the regional differences 
observed by CaSTRR imaging. Finally there are two potential mechanisms for signal loss 
due to the gradient echo readout used to acquire CaSTRR images. The first is rapid T2* 
decay, and while this study attempts to minimize this effect by using the shortest possible 
echo time, a multi-echo acquisition would allow for a more complete compensation. The 
second is sensitivity to susceptibility artifacts at air-tissue interfaces. This can be seen as a 
signal loss adjacent to the ear canals, and in this study we were forced to examine only 
those superior regions of the brain that were not affected by this artifact. For studies 
involving deep brain structures it may be necessary to separately acquire a B1 field map to 
correct for susceptibility variation. 
In conclusion, the CaSTRR method produced maps of BBPC in mice with quality 
comparable to the current standard method while requiring far less acquisition time. This 
enables voxel-wise, empirical correction of CBF maps for regional and inter-subject 
variability in BBPC. These corrected CBF maps demonstrate improved contrast between 
gray and white matter regions. With growing interest in using ASL to measure white matter 
perfusion, this technique may have considerable value in studying pre-clinical models of 
white matter pathologies as well as potential for rapid translation to use in human studies. 
  
43 
 
CHAPTER 4.  BRAIN-BLOOD PARTITION COEFFICIENT AND CEREBRAL 
BLOOD FLOW IN CANINES USING CALIBRATED SHORT TR 
RECOVERY (CASTRR) CORRECTION METHOD 
4.1 Introduction 
When using tracer-based techniques like arterial spin labeling (ASL) to quantify 
cerebral blood flow (CBF), it is necessary to determine the partition coefficient of the tracer 
between the perfused tissue and the arterial blood. ASL is a non-invasive, quantitative 
magnetic resonance imaging (MRI) technique that uses magnetically labeled protons in the 
water molecules of the blood as the tracer [25, 53, 87]. So in the case of ASL, the relevant 
partition coefficient is the brain-blood partition coefficient of water (BBPC) which is the 
ratio of the solubility of water in brain tissue to the solubility of water in the blood. The 
BBPC is tissue specific and varies with age, species, pathology, and brain region [57, 60-
62]. This means that BBPC should be determined experimentally for each subject. 
However, the standard practice in ASL studies is to assume a constant BBPC value 
of 0.9mL/g for all regions of the brain regardless of the known variability of this parameter 
[53, 57]. This assumption is made because the previously published MRI methods to 
experimentally determine BBPC required prohibitively long acquisition times and ASL 
studies were generally focused on gray matter perfusion where BBPC variability was 
assumed to be small [58, 62]. A recent study in mice at 7T reported an 87% reduction in 
the acquisition time for BBPC maps using an MRI technique called calibrated short TR 
recovery (CaSTRR) [134]. Like previous methods, CaSTRR determines relative proton 
density using a series of gradient echo acquisitions with varying repetition times (TR) and 
then calibrates the proton density map using a set of deuterium doped phantoms which 
provide an absolute scale of water content. The method is accelerated in CaSTRR by using 
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shorter TR values and using gadolinium doped water phantoms to acquire similar quality 
BBPC maps in a fraction of the time. 
The goal of this study is to apply the CaSTRR technique to a cohort of healthy 
canines using a protocol suited for application in humans at 3T. To do so we acquired 
BBPC images using a CaSTRR protocol adapted for use on a 3T human scanner. We then 
acquired CBF maps using pseudo-continuous ASL (pCASL) to assess the effect of BBPC 
correction on CBF maps, and high resolution anatomical images using magnetization 
prepared rapid acquisition gradient echo (MPRAGE) to facilitate segmentation and 
coregistration. Finally, we compare two methods of normalizing the proton density maps 
using the doped water phantoms and using blood water content derived from hematocrit 
values. 
4.2 Methods 
4.2.1 Animal Model 
All animal experiments were performed in accordance with NIH guidelines and 
approved by the University of Kentucky Institutional Animal Care and Use Committee 
(approval number #2017-2680). Middle aged beagles (n=17, age = 5.0-8.0 yrs, male = 
24%) were acquired as part of a longitudinal study on aging and Alzheimer’s disease. The 
scans in this report represent pretreatment observations, and all animals were healthy at the 
time of their scans. The animals were anesthetized during the MRI procedure using 3-4 
mg/Kg propofol for induction and 1-4% isoflurane mixed with air for maintenance. 
Respiratory rate, heart rate, body temperature, and blood pressure were monitored and 
maintained throughout the procedure.  Two 5 mL vials of blood were drawn from the 
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jugular vein using ethylenediaminetetraacetate (EDTA) treated vials. One of these was 
placed in the scanner with the animal according to the CaSTRR protocol, and the other was 
sent for laboratory analysis including hematocrit (ANTECH Diagnostics, Louisville, KY, 
USA). 
4.2.2 Scanning procedure 
MRI experiments were performed using a 3T Siemens Trio scanner (Siemens, 
Erlangen, Germany) at the MRI and Spectroscopy Center at the University of Kentucky. 
The animal was placed prone with the head resting in a 155 mm diameter, 15 channel 
transmit/receive birdcage coil commonly used for scanning human knees. The doped water 
phantoms along with blood sample were centered on the top of the head. The CaSTRR, 
pCASL, and MPRAGE acquisitions were all acquired in a single scanning session. 
4.2.3 Calibrated Short TR Recovery Imaging 
For the CaSTRR proton density measurements a series of 2-D image stacks were 
acquired using a phase-spoiled, fast low-angle shot gradient echo (FLASH-GRE) sequence 
with varying repetition times (TR = 125, 250, 500, 1000, 2000 ms) [134]. The shortest 
possible echo time (TE = 1.9 ms) was used to minimize T2* decay. Image matrix 
parameters were: field of view = 135 x 124 mm, matrix = 96 x 88, in-plane resolution = 
1.4 x 1.4 mm, slice thickness = 3 mm, number of slices = 30, flip angle = 90°, acquisition 
time = 4 minutes. (Fig. 4.1-A) 
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Figure 4.1 Explanation of CaSTRR and pCASL methods used in this study.  
CaSTRR utilizes a series of FLASH-GRE acquisitions with varying TR which include a 
blood sample and gadolinium-doped deuterium samples placed on the head (A). An 
exponential regression is fit to the signal recovery curve for each voxel (B) yielding a 
map of relative proton density values (C). The relative proton density values are 
calibrated using either water content estimated from hematocrit (D) or the scale of water 
content present in the phantoms (E). Uncorrected CBF maps are derived from pCASL 
acquisitions (F) and are corrected on a voxel-wise basis using the BBPC map normalized 
to the phantoms to create a corrected map of CBF (G). 
 
Qualitative proton density maps were calculated in a voxel-wise manner by fitting 
the signal recovery curve to the mono-exponential equation S= M0*[1-e^(TR/T1)] to yield 
a map of M0 in arbitrary units. Next a Bayesian bias field correction was applied to the M0 
maps to account for inhomogeneity in the receiver coil profile [135]. The low spatial 
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frequency bias field was calculated using 4th order polynomials and 6 Gaussian 
components, and to avoid artificially attenuating the higher signal water phantoms, the 
phantoms were excluded from the bias field estimation. (Fig. 4.1-B,C) 
The M0 maps were calibrated to absolute water content in two ways. The first 
follows the previously published CaSTRR technique which uses a series of 5 phantoms 
containing mixtures of deuterium oxide and distilled water at 40, 30, 20, 10, and 0% [134]. 
Because the deuterium oxide does not produce signal in MRI this creates a scale of know 
water concentration from 60-100% water. These phantoms were also doped with 0.18mM 
gadobutrol (Gadavist, Bayer Healthcare Pharmaceuticals, Whippany NJ, USA) to reduce 
the longitudinal relaxation rate (T1) to be similar to the T1 of brain tissue (≈ 1.2s). Next a 
linear regression was calculated based on the average M0 value in each phantom and its 
known water content, and every voxel in the image was normalized to the resultant 
equation. However, we observed a quadratic relationship between the average M0 values 
of the tissues and the average M0 value of the phantoms such that the relationship between 
phantom proton density and tissue proton density was not constant. In order to correct for 
this, the quadratic term of the relationship was subtracted from the blood and tissue M0 
values prior to normalization. (Fig. 4.1-E) 
The second method of calibrating M0 maps utilized the hematocrit value to 
determine the absolute water content of the blood sample. Water content was determined 
according to the equation WCblood = -0.271*Hct + 0.912 [136]. The M0 image was then 
normalized such that the average water content in the blood sample matched the average 
value calculated according to hematocrit. 
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BBPC maps were generated for both normalization methods by comparing the 
measured water content of each voxel in the brain to the average water content of the blood 
using the equation BBPC = WCbrain/(WCblood*1.04g/mL). (Fig. 4.1-D) 
4.2.4 Cerebral Blood Flow and Anatomical Imaging 
The CBF maps were acquired using a pCASL sequence with a three-dimensional 
gradient and spin echo (GRASE) readout [53]. The acquisition parameters were as follows: 
TR/TE/TI = 3200/16/1400 ms, field of view = 270 x 250 x 90 mm, matrix = 96 x 88, 
resolution = 3 x 3 x  3 mm, acquisition time = 6:15 minutes. (Fig. 4.1-F) 
Because the original CBF maps were created with an assumed BBPC value of 0.9 
mL/g, corrected maps were generated by dividing the entire map by this value and then 
multiplying by the BBPC map in a voxel-wise manner. BBPC correction was performed 
using the BBPC maps generated using the gadolinium doped water phantoms. (Fig. 4.1-G) 
Contrast to noise ratio (CNR) was calculated according to the equation CNR = 
(Meangray – Meanwhite)/Pooled Standard Deviation [137]. 
Anatomical images were acquired using a high resolution T1 weighted 
magnetization prepared rapid acquisition gradient echo (MPRAGE) sequence as 
recommended for optimal use with FreeSurfer [138]. Scan parameters were: TR/TE= 
1690/2.56 ms, flip angle = 12°, field of view = 320 x 320 x 160 mm, matrix = 256 x 256 x 
128, resolution = 0.8 x 0.8 x 0.8 mm, acquisition time = 10:49 minutes. 
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4.2.5 Image Analysis 
All images were coregistered by first resampling the anatomical volumes to match 
the slice thickness of the CaSTRR and pCASL acquisitions. The CaSTRR and pCASL 
volumes were then registered to the anatomical using an intensity-based registration 
algorithm in Matlab (Mathworks, Natick MA, USA) [139]. The brain region of interest 
was extracted manually, and then segmented into gray and white regions of interest using 
an expectation maximization algorithm with classes for gray matter, white matter, and 
cerebrospinal fluid [140]. To avoid partial volume effects, the gray and white matter 
regions of interest in each slice were eroded by two pixels. Due to image inhomogeneities 
in the MPRAGE acquisitions in some animals, the segmentation algorithm often failed to 
adequately segment gray and white matter regions in the most rostral and caudal sections 
of the brain. While the BBPC maps did not display these inhomogeneities, the regions of 
interest were not reliable for analysis. For this reason, we chose to include only the 
centermost 10 slices in our analysis. These regions of interest were then applied to the 
BBPC and CBF maps. All image analysis was performed in Matlab (Mathworks, Natick 
MA, USA). 
4.2.6 Statistical Analysis 
All statistical analysis was performed in Matlab. Data is expressed as mean ± 
standard deviation. Gray and white matter comparisons were assessed using three-way 
analysis of covariance with age, sex, and tissue type as independent variables. Linear 
regressions against age were also controlled for sex. Values of p < 0.05 were considered 
statistically significant. 
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4.3 Results 
4.3.1 BBPC is Higher in Gray Matter than in White Matter 
The first comparison was drawn on BBPC maps generated using the previously 
published CaSTRR method of normalizing to the gadolinium doped water phantoms (Fig. 
4.1-E). The average BBPC in gray matter was 0.83 ± 0.05 mL/g which is 5.6% higher than 
the BBPC in white matter (0.78 ± 0.04 mL/g, p = 0.007) (Fig. 4.2-B). When plotted against 
age, neither the gray nor the white matter regions of interest demonstrated a significant 
correlation over the age range studied (gray matter: p = 0.645, white matter: p = 0.483. 
 
Figure 4.2 Average BBPC vs Age. Gray matter (blue) and white matter (red) regions of 
interest are plotted against age (A) and as group averages (B). Regions corresponding to 
the same animal are connected with a vertical dotted line. No significant linear 
correlation to age was found in either region. Average BBPC in gray matter was 5.6% 
higher than in white matter (BBPCgray= 0.83 ± 0.05mL/g, BBPCwhite 0.78 ± 0.04 mL/g, ** 
indicates p< 0.01, error bars represent 1 standard deviation) 
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4.3.2 Gray Matter CBF is Negatively Correlated with Age 
Next, gray and white matter perfusion were compared in uncorrected CBF maps 
(Fig. 4.1-F) and again in corrected CBF maps (Fig. 4.1-G) which used the standard 
CaSTRR derived BBPC maps for correction (Fig. 4.1-E). Gray matter has 45% higher CBF 
than white matter in the uncorrected CBF maps (CBFgray = 81 ± 12 mL/100g/min,  CBFwhite 
= 56 ± 12 mL/100g/min, p < 0.001) and 53% higher CBF in the maps corrected for BBPC 
(cCBFgray = 73 ± 13 mL/100g/min,  cCBFwhite = 49 ± 11 mL/100g/min, p < 0.01) (see 
Figure 3-B). Gray matter demonstrated a significant negative correlation with age with a 
reduction of 7.5 ± 2.1 mL/100g/min each year or 9% of the average perfusion (CBFgray = 
128 – 7.5 * Age mL/100g/min, p = 0.003). The corrected CBF maps also revealed a 
reduction of 6.6 ± 2.6 mL/100g/min/yr (cCBFgray = 117 – 6.6 * Age mL/100g/min, p = 
0.02), but this relationship was not significantly different in the corrected maps than the 
uncorrected (p = 0.81). While there appears to be a downward trend in white matter 
perfusion with age, this correlation was not statistically significant in the uncorrected CBF 
maps (p = 0.20) or the corrected maps (p = 0.33) (Fig. 4.3-A). 
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Figure 4.3 Gray and White CBF versus Age  (A). Plotted points represent uncorrected 
average CBF for each animal. Gray matter CBF demonstrates a negative linear 
correlation with age in both uncorrected CBF maps (CBFgray = 128 – 7.5 * Age 
mL/100g/min) and maps corrected using measured BBPC (cCBFgray = 117 – 6.6 * Age 
mL/100g/min). Linear regression was not significant in the white matter region in either 
case. When considered as group averages (B), the gray matter has significantly higher 
CBF in both uncorrected (CBFgray = 81 ± 12 mL/100g/min,  CBFwhite = 56 ± 12 
mL/100g/min), and corrected maps (cCBFgray = 73 ± 13 mL/100g/min,  cCBFwhite = 49 ± 
11 mL/100g/min). (* indicates p< 0.05, ** indicates p< 0.01, *** indicates p< 0.001, 
error bars represent 1 standard deviation. 
4.3.3 BBPC Correction improves contrast to noise ratio in CBF maps 
Next, the CNR of corrected CBF maps (Fig. 4.1-G) was compared to uncorrected 
CBF maps (Fig. 4.1-F). On average BBC correction improved CNR between gray and 
white matter regions of the CBF maps by 3.6% (95% confidence interval = 0.6 – 6.5%). 
The average uncorrected CNR was 0.81 and the average corrected CNR was 0.84. 
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4.3.4 BBPC Values Generated Using Hematocrit Agree with Values Generated Using 
Phantoms 
The final comparison was between maps normalized using the doped water 
phantoms (Fig. 4.1-E) to ones normalized using hematocrit derived blood water content 
(Fig. 4.1-D), we observed positive correlations between the BBPC values generated using 
these two methods. The Pearson correlation was R2 = 0.81 for gray matter indicating strong 
correlation between these measures in this region (Fig. 4.4-A). Due to higher variability in 
the white matter regions the correlation was moderate in white matter (R2 = 0.59) (see Fig. 
4.4-C). The measured BBPC values were slightly lower in maps normalized to hematocrit, 
though not statistically different, and Bland-Altman analysis demonstrates no significant 
bias in either region of interest (Fig. 4.4-B,D). Again the BBPC in gray matter was 5.9% 
higher than in white matter when using hematocrit to normalize (BBPCgray = 0.81 ± 0.06 
mL/g, BBPCwhite = 0.77 ± 0.05 mL/g, p = 0.02).  
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Figure 4.4 Correlation of BBPC values in maps normalized according to hematocrit 
with values in maps normalized to the gadolinium-doped phantoms. Correlation is very 
strong for the gray matter BBPC values (R2 = 0.81) (A) and moderately strong for white 
matter (R2 = 0.59) (C). Bland-Altman analysis demonstrates no significant bias in either 
gray (B) or white matter values (D). 
4.4 Discussion 
The CaSTRR technique represents a significant improvement in the acquisition 
speed of BBPC maps. A previously published report measuring BBPC using a 1.5T human 
scanner acquired a single slice of the BBPC map in approximately 30 minutes [58]. In this 
study we were able to produce BBPC maps of sufficient quality to perform voxel-wise 
correction of CBF maps with coverage of the entire brain using a CaSTRR acquisition 
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protocol that only required 4 minutes of scan time. This is an improvement over the 
reported CaSTRR technique in mice which required 17 minutes of scan time due to the 
much higher resolution requirement of scanning small animals at 7T [134]. A four minute 
scan time is comparable to the acquisition time of the pCASL technique for CBF. The 
experiment was also done with commercially available equipment and pulse sequences that 
are directly applicable for use with a human subject. Furthermore, the CaSTRR scans were 
performed with the same birdcage receive coil that was used for the pCASL acquisitions. 
This was not possible when scanning mice at 7T and represents a significant advantage of 
scanning at lower fields. The greatly reduced scan time and ready availability of equipment 
and pulse sequences demonstrate that CaSTRR is a feasible approach to correct CBF maps 
using empirically measured BBPC values instead of assuming a constant value for all tissue 
types, pathologies, ages, and species. This technique has the potential for rapid translation 
to use in human studies. 
While BBPC has not been previously reported in canines, our reported values of 
0.83 ± 0.05 mL/g in gray matter and 0.78 ± 0.04 mL/g in white matter are lower than 
published reports in humans, non-human primates, and mice [57, 61, 62]. One possible 
reason for this is the temperature discrepancy between the blood sample and the brain 
tissue. When measured at room temperature instead of physiologic temperature, the proton 
density of the blood could be overestimated by as much as 5% causing BBPC to be 
underestimated by the same amount [141]. The amount of inter-species variability in BBPC 
values is further evidence for the importance of empirical BBPC correction when 
quantifying CBF. 
56 
 
The correlation between the two methods of normalization represents a distinct 
advantage of this study. Our results suggest that the CaSTRR technique can be further 
simplified by omitting the gadolinium doped water phantoms. This would also obviate the 
need for correcting the non-linear signal increases observed in the water phantoms in this 
study. 
Another significant advantage of this study is the use of Bayesian bias field 
correction to account for inhomogeneities in the receiver coil sensitivity profile. The 
CaSTRR method described in mice assumed a sufficiently homogenous profile in the 
birdcage receive coil, but observed significant signal loss near the large ear canals of the 
mouse [134]. Other BBPC studies attempted to correct for bias field using a separate 
measurement on a uniform phantom [58, 62], but it is unlikely that the receiver profile 
would be the same when measuring the non-uniform tissue of a live subject.  
Arterial spin labeling has an inherently low signal to noise ratio because it is a 
subtractive technique. Including an empirical measurement of BBPC to the quantification 
of CBF will increase noise, as we observed in the greater variance of CBF values in the 
corrected maps. However, there was an improvement in contrast to noise between areas 
with significantly different BBPC values despite this addition of noise. This could become 
important when studying perfusion in models of pathology where the tissue composition 
is likely to change.  
There are many examples of pathologies that could affect water balance in the 
brain.  Brain edema caused by ischemia [142], infection [143], or trauma [144] can cause 
localized increases in free water and potentially affect the BBPC. Another important field 
of interest where ASL is commonly used is the study of Alzheimer’s disease (AD). The 
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deposition of hydrophobic amyloid-β protein, which is a hallmark of AD pathology, may 
reduce the BBPC in regions of plaque development [145]. AD occurs in the context of 
aging and typically causes pronounced brain atrophy [146]. Both of these could result in 
reduced brain water content and therefore reduced BBPC. Both brain volume [147] and 
hematocrit [148] can also change significantly with a subject’s level of hydration. So while 
our result showed that BBPC correction did not affect the observed relationship between 
CBF and age between the ages of 5-8 year, it is possible that BBPC correction could 
improve sensitivity in studies where BBPC is expected to change significantly. In future 
studies, CaSTRR imaging could be used to study how BBPC changes with pathology and 
could also be used to account for water balance effects when measuring perfusion. 
In conclusion, this study demonstrates the feasibility of CaSTRR as a method to 
correct CBF measurements for regional and inter-subject variability in BBPC, and 
demonstrates the potential for use in human studies. 
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CHAPTER 5.  DISCUSSION 
5.1 Overview 
The impetus of this dissertation project was a clinical hypothesis regarding cerebral 
perfusion in the setting of Down syndrome (DS). Namely, we hypothesized that people 
with DS would have compromised cerebral blood flow (CBF) despite a protective 
cardiovascular risk profile. In the study described in chapter 2, we were able to demonstrate 
reduced CBF in people with DS over the age of 54 years. This represents the first 
quantitative perfusion imaging study in DS and is particularly interesting for the delayed 
pattern of perfusion deficits in this population. This had not been described previously and 
contrasts with the typical pattern of early CBF deficits in familial Alzheimer’s disease 
(AD).  
However, limitations in the currently available methods to measure brain-blood 
partition coefficient (BBPC) prevented us from accounting for potential changes in brain 
water content. Such changes could arise in the setting of DS or AD from aging, atrophy, or 
the deposition of hydrophobic amyloid-β (A-β) plaques. This prompted the development 
of the rapid BBPC method described in chapter 3. Calibrated short TR recovery (CaSTRR) 
imaging in mice reduced acquisition time by 87% and improved contrast between gray and 
white matter regions in corrected CBF maps. 
The CaSTRR technique was then translated for use with equipment suitable for 
humans in chapter 4. Healthy canines were scanned using the same protocol and equipment 
as would be used with human subjects. This study represents the first report of BBPC 
values in canines and establishes a negative correlation between gray matter perfusion and 
age. Further improvements are also made to the CaSTRR protocol such that acquisition 
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time is reduced to 4 minutes and it is demonstrated that gadolinium-doped phantoms are 
not necessary because hematocrit can serve as a proxy value for blood water content. These 
simplifications and the results of this study demonstrate the feasibility of using CaSTRR 
for empirical BBPC correction of CBF maps. 
5.2 Future Directions 
Despite the improvements, there are still limitations that will need to be addressed 
in the future. First the CaSTRR technique requires a sample of the subject’s blood to be 
placed in the scanner during acquisition. While drawing a blood sample is a routine 
procedure, future advancements to obviate this step would further simplify the method. 
This could potentially be accomplished by acquiring higher resolution CaSTRR images 
such that the water content of the blood could be measured in the sagittal sinus of the image. 
In our studies of mice and dogs, the sagittal sinuses were not large enough to accomplish 
this, but it may be possible to do so with the larger anatomy of a human. Pulsatile flow in 
the sagittal sinuses poses a challenge to such a strategy, however the constant inflow of 
unsaturated blood may result in a flat signal recovery curve from which the blood water 
content may be determined. Second, the post-processing of CaSTRR images to create 
BBPC maps and use them to correct CBF maps is not currently optimized. The final 
corrected CBF map is a result of several steps of coregistration and performing an 
exponential regression on every voxel in the CaSTRR acquisition. This is computationally 
expensive and would benefit from optimization in the future. Image analysis is also 
currently limited to semi-automated methods that require user input. Fully-automated 
methods would drastically reduce post-processing time. 
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Having established proof of concept in both small animal scanners and human 
scanners, the next step will be to apply the CaSTRR technique in clinical and pre-clinical 
settings where BBPC is expected to change. While the final translational step to application 
in humans remains for future studies, the results of chapter 4 are promising that CaSTRR 
will be effective in humans as it has been in mice and dogs. Once accomplished there are 
a variety of pathologies and small animal models of disease to which CaSTRR imaging 
could be applied. 
For example, there are numerous studies in humans and small animals that use ASL 
to track perfusion in AD. It is reasonable to think that atrophy and A-β accumulation could 
affect brain water content in this disease, so CaSTRR represents a potential tool to track 
changes in BBPC over time and determine the sensitivity of ASL to those changes. Because 
ASL and CaSTRR imaging are non-invasive and non-radiative, they are well suited for use 
in longitudinal studies.  
The original clinical question of this dissertation concerned DS and we recognized 
the inability to account for BBPC variability as a limitation of that study. It would be 
appropriate to apply CaSTRR as a method to overcome that limitation and determine if 
there is a change in BBPC concomitant with the observed change in CBF. While small 
animal models of DS do exist, they are often challenging to correlate with the human 
condition. However, due to the simplicity of CaSTRR it is feasible to include this method 
as part of ongoing clinical experiments that already use MRI. 
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Other pathologies or treatments could yield significant changes in BBPC as well. 
Brain edema as the result of ischemic injury, cranial trauma, or infection could have acute, 
local effects on BBPC. These would be an interesting application of CaSTRR to determine 
if excess free water could confound CBF deficits measured by ASL. There is also some 
preliminary evidence that pharmacological treatment could affect BBPC. When treated 
with rapamycin, mice demonstrate an increase in BBPC in the hippocampus. This could be 
significant when considering the role of ASL to track treatment efficacy, and it highlights 
the importance of controlling for BBPC variability using a technique like CaSTRR. 
5.3 Innovation 
The results presented in this dissertation represent a significant advancement to the 
fields of neuroimaging and neuroscience in the following ways. First, the study in chapter 
2 is the first to demonstrate compromised perfusion in people with DS despite their lack of 
typical risk factors for cerebrovascular disease. This contributes to the understanding of the 
role of cerebrovascular disease in the progression of AD. Second, the development of the 
CaSTRR technique overcomes the significant limitation of excessively long scan times to 
measure BBPC. This allows for more accurate quantification of CBF using BBPC 
correction, which is particularly important when studying pathologies where brain water 
content is likely to be disrupted. The results from chapters 3 and 4 demonstrate the benefit 
of CaSTRR to improve contrast in CBF maps. Third, the results of chapter 4 represent the 
first report of BBPC values in canines. These vary from the values reported for humans, 
mice, and monkeys highlighting the importance of using empirical values for BBPC when 
quantifying CBF. Finally, the CaSTRR technique was translated in chapter 4 for future use 
with human subjects. This demonstrate the great translational value of this project, which 
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spans three species and has produced a valuable technique for use in both clinical and pre-
clinical research. 
5.4 Conclusion 
In summary, we have shown that MRI-based CBF measurement is a valuable 
method to identify neuronal disease progression in pathologies like DS. However, a 
traditional assumption of constant BBPC has limited CBF studies from accounting for the 
potential confounding factor of changes in brain water content. We addressed this issue 
with the development of novel CaSTRR methods, which can be applied in both animal and 
human scanners. With this improvement, it is expected that CBF can be even more 
sensitive to neuronal function changes and in the future will serve as invaluable biomarker 
for identifying disease progression and treatment efficacy. 
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